+Compare
MDXG
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
921.7M

MDXG MiMedx Group Forecast, Technical & Fundamental Analysis

a manufacturer of patent protected regenerative biomaterial products and bioimplants

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for MDXG with price predictions
07:00 PM EST Dec 05, 2023

MDXG in upward trend: price may ascend as a result of having broken its lower Bollinger Band on November 09, 2023

MDXG may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 31 cases where MDXG's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 14, 2023. You may want to consider a long position or call options on MDXG as a result. In of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for MDXG just turned positive on November 13, 2023. Looking at past instances where MDXG's MACD turned positive, the stock continued to rise in of 40 cases over the following month. The odds of a continued upward trend are .

MDXG moved above its 50-day moving average on November 17, 2023 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for MDXG crossed bullishly above the 50-day moving average on November 24, 2023. This indicates that the trend has shifted higher and could be considered a buy signal. In of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MDXG advanced for three days, in of 314 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for MDXG moved out of overbought territory on December 05, 2023. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 44 similar instances where the indicator moved out of overbought territory. In of the 44 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 13 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDXG declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for MDXG entered a downward trend on November 15, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MDXG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: MDXG's P/B Ratio (714.286) is very high in comparison to the industry average of (20.710). P/E Ratio (0.000) is within average values for comparable stocks, (137.900). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (7.704). Dividend Yield (0.000) settles around the average of (0.035) among similar stocks. P/S Ratio (2.949) is also within normal values, averaging (330.425).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sorrento Therapeutics, Inc. (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.3B. The market cap for tickers in the group ranges from 402 to 464.61B. NVO holds the highest valuation in this group at 464.61B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 7%. For the same Industry, the average monthly price growth was 6%, and the average quarterly price growth was 27%. IVBT experienced the highest price growth at 1,413%, while IBIO experienced the biggest fall at -61%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -6%. For the same stocks of the Industry, the average monthly volume growth was 2% and the average quarterly volume growth was 64%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 58
SMR Rating: 94
Profit Risk Rating: 94
Seasonality Score: 27 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I. Advisor
published Earnings

MDXG is expected to report earnings to rise 120.00% to 10 cents per share on July 26

MiMedx Group MDXG Stock Earnings Reports
Q2'18
Est.
$0.11
Q3'23
Est.
$0.05
Q2'23
Beat
by $0.02
Q1'23
Beat
by $0.06
Q4'22
Beat
by $0.02
The last earnings report on October 30 showed earnings per share of 5 cents, meeting the estimate of 5 cents. With 511.72K shares outstanding, the current market capitalization sits at 921.70M.
A.I. Advisor
published General Information

General Information

a manufacturer of patent protected regenerative biomaterial products and bioimplants

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
1775 West Oak Commons Court, NE
Phone
+1 770 651-9100
Employees
867
Web
https://www.mimedx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PWIYX17.120.10
+0.59%
PACE International Equity Y
VMCCX47.27N/A
N/A
Virtus KAR Mid-Cap Core C
IGAAX34.14-0.05
-0.15%
American Funds Intl Gr and Inc A
ISGHX11.73-0.04
-0.34%
Columbia Integrated Small Cap Gr R
JABIX10.88-0.04
-0.37%
JHancock Real Estate Securities R6

MDXG and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDXG has been loosely correlated with IMGN. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if MDXG jumps, then IMGN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDXG
1D Price
Change %
MDXG100%
+0.19%
IMGN - MDXG
49%
Loosely correlated
+0.45%
MDGL - MDXG
48%
Loosely correlated
+0.54%
AXON - MDXG
47%
Loosely correlated
+0.27%
INVA - MDXG
45%
Loosely correlated
-1.74%
PRTA - MDXG
40%
Loosely correlated
+4.80%
More

Groups containing MDXG

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDXG
1D Price
Change %
MDXG100%
+0.19%
drugs
(undefined stocks)
38%
Loosely correlated
+1.33%
biotechnology
(undefined stocks)
36%
Loosely correlated
+1.71%
generic products
(undefined stocks)
30%
Poorly correlated
+0.72%
stem cells
(undefined stocks)
27%
Poorly correlated
+2.38%
biological
(undefined stocks)
26%
Poorly correlated
+2.01%